文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

羟氯喹对COVID-19住院患者14天临床状态的影响:一项随机临床试验

Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01
一句话结论住院COVID-19成人使用羟氯喹较安慰剂未显著改善14天临床状态,不推荐用于该人群治疗。

这项多中心、盲法、安慰剂对照RCT在美国34家医院纳入479例因SARS-CoV-2感染住院的成人,随机接受羟氯喹(400mg每日两次×2次,后200mg每日两次×8次)或安慰剂。第4次期中分析因无效提前终止。14天7分类序贯量表临床状态两组无显著差异(中位6 vs 6;aOR 1.02,95%CI 0.73–1.42),12项次要终点均无显著差异,28天死亡率10.4% vs 10.6%(aOR 1.07,95%CI 0.54–2.09)。结果不支持羟氯喹用于住院COVID-19成人。

要点

  • 住院COVID-19成人中,羟氯喹组与安慰剂组14天临床状态无显著差异(aOR 1.02,95%CI 0.73–1.42)。
  • 28天死亡率羟氯喹组10.4%(25/241) vs 安慰剂组10.6%(25/236),绝对差-0.2%(95%CI -5.7%至5.3%)。
  • 12项次要终点均无显著差异,包括28天死亡率(aOR 1.07,95%CI 0.54–2.09)。
  • 试验因无效在第4次期中分析提前终止,计划样本510例,实际479例。
  • 人群基线:中位年龄57岁,20.1%在ICU,6.7%接受有创机械通气或ECMO。

适用人群与场景

  • 美国34家医院因SARS-CoV-2感染伴呼吸道症状住院的成人,2020年4月2日至6月19日入组。
  • 基线:中位年龄57岁,44.3%女性,20.1%在ICU,46.8%接受无正压的补充氧,11.5%接受无创通气或经鼻高流量氧,6.7%接受有创机械通气或ECMO。
  • 随机前症状中位持续5天(IQR 3–7天)。

诊断标准与关键阈值

  • 主要终点为随机后14天临床状态,采用7分类序贯量表:1=死亡至7=出院并能正常活动。
  • 主要终点用多变量比例优势模型分析,aOR>1.0表示羟氯喹组结局更优。

处置流程与药物剂量

  • 羟氯喹组:400 mg 每日两次×2次,随后200 mg 每日两次×8次(原文未注明给药途径)。
  • 对照组:安慰剂(原文未注明剂量与途径)。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 多中心、盲法、安慰剂对照RCT,美国34家医院,计划样本510例,因无效在第4次期中分析提前终止于479例。
  • 随机分组:羟氯喹242例,安慰剂237例;433例(90.4%)完成14天主要终点评估,其余采用插补。
  • 14天序贯量表评分两组无显著差异:中位(IQR)6(4–7) vs 6(4–7);aOR 1.02(95%CI 0.73–1.42)。
  • 12项次要终点均无显著差异。
  • 28天死亡:羟氯喹组25/241(10.4%) vs 安慰剂组25/236(10.6%);绝对差-0.2%(95%CI -5.7%至5.3%);aOR 1.07(95%CI 0.54–2.09)。

证据类型、等级与局限

  • 证据类型:多中心、盲法、安慰剂对照随机临床试验(RCT)。
  • 局限:因无效提前终止;原文未提及其他局限。

对床旁实践的改变

  • 住院COVID-19成人不应使用羟氯喹治疗,因较安慰剂未改善14天临床状态。
  • 该结论适用于因SARS-CoV-2感染伴呼吸道症状住院的成人,不适用于门诊或非住院人群(原文未纳入)。

指南或共识出处

  • ClinicalTrials.gov: NCT04332991。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Data on the efficacy of hydroxychloroquine for the treatment of coronavirus disease 2019 (COVID-19) are needed.

OBJECTIVE: To determine whether hydroxychloroquine is an efficacious treatment for adults hospitalized with COVID-19.

DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, blinded, placebo-controlled randomized trial conducted at 34 hospitals in the US. Adults hospitalized with respiratory symptoms from severe acute respiratory syndrome coronavirus 2 infection were enrolled between April 2 and June 19, 2020, with the last outcome assessment on July 17, 2020. The planned sample size was 510 patients, with interim analyses planned after every 102 patients were enrolled. The trial was stopped at the fourth interim analysis for futility with a sample size of 479 patients.

INTERVENTIONS: Patients were randomly assigned to hydroxychloroquine (400 mg twice daily for 2 doses, then 200 mg twice daily for 8 doses) (n = 242) or placebo (n = 237).

MAIN OUTCOMES AND MEASURES: The primary outcome was clinical status 14 days after randomization as assessed with a 7-category ordinal scale ranging from 1 (death) to 7 (discharged from the hospital and able to perform normal activities). The primary outcome was analyzed with a multivariable proportional odds model, with an adjusted odds ratio (aOR) greater than 1.0 indicating more favorable outcomes with hydroxychloroquine than placebo. The trial included 12 secondary outcomes, including 28-day mortality.

RESULTS: Among 479 patients who were randomized (median age, 57 years; 44.3% female; 37.2% Hispanic/Latinx; 23.4% Black; 20.1% in the intensive care unit; 46.8% receiving supplemental oxygen without positive pressure; 11.5% receiving noninvasive ventilation or nasal high-flow oxygen; and 6.7% receiving invasive mechanical ventilation or extracorporeal membrane oxygenation), 433 (90.4%) completed the primary outcome assessment at 14 days and the remainder had clinical status imputed. The median duration of symptoms prior to randomization was 5 days (interquartile range [IQR], 3 to 7 days). Clinical status on the ordinal outcome scale at 14 days did not significantly differ between the hydroxychloroquine and placebo groups (median [IQR] score, 6 [4-7] vs 6 [4-7]; aOR, 1.02 [95% CI, 0.73 to 1.42]). None of the 12 secondary outcomes were significantly different between groups. At 28 days after randomization, 25 of 241 patients (10.4%) in the hydroxychloroquine group and 25 of 236 (10.6%) in the placebo group had died (absolute difference, -0.2% [95% CI, -5.7% to 5.3%]; aOR, 1.07 [95% CI, 0.54 to 2.09]).

CONCLUSIONS AND RELEVANCE: Among adults hospitalized with respiratory illness from COVID-19, treatment with hydroxychloroquine, compared with placebo, did not significantly improve clinical status at day 14. These findings do not support the use of hydroxychloroquine for treatment of COVID-19 among hospitalized adults.

TRIAL REGISTRATION: ClinicalTrials.gov: NCT04332991.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Self WH, Semler MW, Leither LM, et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020. PMID: 33165621. doi:10.1001/jama.2020.22240

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。